Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "[The PI3K/mammalian Target of Rapamycin (mTOR) pathway is often aberrantly activated in rhabdomyosarcoma (RMS) and represents a promising therapeutic target.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

• NP736103.RAWbrzkvTMPW6kapDSnE3CNGtD2Mvq5dmXw6ubGY9hzcU130_assertion description "[The PI3K/mammalian Target of Rapamycin (mTOR) pathway is often aberrantly activated in rhabdomyosarcoma (RMS) and represents a promising therapeutic target.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP736103.RAWbrzkvTMPW6kapDSnE3CNGtD2Mvq5dmXw6ubGY9hzcU130_provenance.
• NP918322.RAh_YN2kCyL1gO62KvlaNvqmk5P3tX1lUzBPpDuwRM-2c130_assertion description "[The PI3K/mammalian Target of Rapamycin (mTOR) pathway is often aberrantly activated in rhabdomyosarcoma (RMS) and represents a promising therapeutic target.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP918322.RAh_YN2kCyL1gO62KvlaNvqmk5P3tX1lUzBPpDuwRM-2c130_provenance.
• NP345456.RAHZff3tiBFmGiL9GcdCV1j7tN0jhCPcOcU7DCTXSfIQw130_assertion description "[The PI3K/mammalian Target of Rapamycin (mTOR) pathway is often aberrantly activated in rhabdomyosarcoma (RMS) and represents a promising therapeutic target.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP345456.RAHZff3tiBFmGiL9GcdCV1j7tN0jhCPcOcU7DCTXSfIQw130_provenance.
• NP567051.RA9n59e2j-dbqAC_uZmWRukngrRbGEg0O4fNHVCnlAZMM130_assertion description "[The PI3K/mammalian Target of Rapamycin (mTOR) pathway is often aberrantly activated in rhabdomyosarcoma (RMS) and represents a promising therapeutic target.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP567051.RA9n59e2j-dbqAC_uZmWRukngrRbGEg0O4fNHVCnlAZMM130_provenance.
• NP425605.RA8K4hz9u93jfa_GO-sQDSkwUcn5chWWdWuzr3vJPfy9Y130_assertion description "[The PI3K/mammalian Target of Rapamycin (mTOR) pathway is often aberrantly activated in rhabdomyosarcoma (RMS) and represents a promising therapeutic target.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP425605.RA8K4hz9u93jfa_GO-sQDSkwUcn5chWWdWuzr3vJPfy9Y130_provenance.
• NP625112.RAQlrWQ_9FTCpNpxev3Dy52Te-ohWS1sX3GKh61fAQmgw130_assertion description "[The PI3K/mammalian Target of Rapamycin (mTOR) pathway is often aberrantly activated in rhabdomyosarcoma (RMS) and represents a promising therapeutic target.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP625112.RAQlrWQ_9FTCpNpxev3Dy52Te-ohWS1sX3GKh61fAQmgw130_provenance.
• assertion description "[The PI3K/mammalian Target of Rapamycin (mTOR) pathway is often aberrantly activated in rhabdomyosarcoma (RMS) and represents a promising therapeutic target.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[The PI3K/mammalian Target of Rapamycin (mTOR) pathway is often aberrantly activated in rhabdomyosarcoma (RMS) and represents a promising therapeutic target.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[The PI3K/mammalian Target of Rapamycin (mTOR) pathway is often aberrantly activated in rhabdomyosarcoma (RMS) and represents a promising therapeutic target.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[The PI3K/mammalian Target of Rapamycin (mTOR) pathway is often aberrantly activated in rhabdomyosarcoma (RMS) and represents a promising therapeutic target.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP621276.RABDEkWo9UP2ANk1uYMg0m8D0Ct80hcZX1W1R3R26Wg6s130_assertion description "[The PI3K/mammalian Target of Rapamycin (mTOR) pathway is often aberrantly activated in rhabdomyosarcoma (RMS) and represents a promising therapeutic target.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP621276.RABDEkWo9UP2ANk1uYMg0m8D0Ct80hcZX1W1R3R26Wg6s130_provenance.
• NP622656.RAs-iXWi2CJFtKgXyEvbXFqIkeHayVB7GRrTN0C4Zwnr8130_assertion description "[The PI3K/mammalian Target of Rapamycin (mTOR) pathway is often aberrantly activated in rhabdomyosarcoma (RMS) and represents a promising therapeutic target.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP622656.RAs-iXWi2CJFtKgXyEvbXFqIkeHayVB7GRrTN0C4Zwnr8130_provenance.
• NP1120107.RAtN3bR4N0GntublNk9_BlKv9onynqHWwIXK04cDIuaLE130_assertion description "[The PI3K/mammalian Target of Rapamycin (mTOR) pathway is often aberrantly activated in rhabdomyosarcoma (RMS) and represents a promising therapeutic target.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1120107.RAtN3bR4N0GntublNk9_BlKv9onynqHWwIXK04cDIuaLE130_provenance.
• NP623970.RA9UV-DVqh0W_Oh5Z1DfvVs4qMoP28zmQV1onOfI2-krA130_assertion description "[The PI3K/mammalian Target of Rapamycin (mTOR) pathway is often aberrantly activated in rhabdomyosarcoma (RMS) and represents a promising therapeutic target.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP623970.RA9UV-DVqh0W_Oh5Z1DfvVs4qMoP28zmQV1onOfI2-krA130_provenance.
• NP1120104.RA9bS3hAh3ngd4pm2eZFJNXODoJjVAw-i9wJQw4qofEDw130_assertion description "[The PI3K/mammalian Target of Rapamycin (mTOR) pathway is often aberrantly activated in rhabdomyosarcoma (RMS) and represents a promising therapeutic target.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1120104.RA9bS3hAh3ngd4pm2eZFJNXODoJjVAw-i9wJQw4qofEDw130_provenance.
• NP1120105.RAz1VpV0PSvZp3Xepk-gR0sK3jUUhm9l7WB7r15C82mec130_assertion description "[The PI3K/mammalian Target of Rapamycin (mTOR) pathway is often aberrantly activated in rhabdomyosarcoma (RMS) and represents a promising therapeutic target.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1120105.RAz1VpV0PSvZp3Xepk-gR0sK3jUUhm9l7WB7r15C82mec130_provenance.
• NP1120106.RA52di2H4PF1HMLlO9PmPhWyrWfe8b3Owe9Hj07XA1fRM130_assertion description "[The PI3K/mammalian Target of Rapamycin (mTOR) pathway is often aberrantly activated in rhabdomyosarcoma (RMS) and represents a promising therapeutic target.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1120106.RA52di2H4PF1HMLlO9PmPhWyrWfe8b3Owe9Hj07XA1fRM130_provenance.